about
A novel Src homology 2 domain-containing molecule, Src-like adapter protein-2 (SLAP-2), which negatively regulates T cell receptor signalingRecent advances in understanding myelofibrosis and essential thrombocythemiaDevelopment of human protein reference database as an initial platform for approaching systems biology in humansThe N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptorA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraA senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferationMolecular identification of β-citrylglutamate hydrolase as glutamate carboxypeptidase 3JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitorsThe Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction.Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.What is the role of amyloid precursor protein dimerization?Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.Helix packing and orientation in the transmembrane dimer of gp55-P of the spleen focus forming virus.JAK2, the JAK2 V617F mutant and cytokine receptors.JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.JAK/STAT signaling in hematological malignancies.Presenilin transmembrane domain 8 conserved AXXXAXXXG motifs are required for the activity of the γ-secretase complexNeurobiology of vascular dementia.Role of interferon alpha/beta receptor chain 1 in the structure and transmembrane signaling of the interferon alpha/beta receptor complex.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Analysis by a highly sensitive split luciferase assay of the regions involved in APP dimerization and its impact on processing.A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms.Role of tyrosine kinases and phosphatases in polycythemia vera.A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.Interferon alpha induces protein kinase C-epsilon (PKC-epsilon) gene expression and a 4.7-kb PKC-epsilon-related transcriptThe Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesHis499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin ReceptorWhole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation.Glycines from the APP GXXXG/GXXXA Transmembrane Motifs Promote Formation of Pathogenic Aβ Oligomers in CellsUncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis.Mining for JAK-STAT mutations in cancer.SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases
P50
Q24292458-622FAD89-F9B2-4305-84DD-049DF39E1437Q26748543-E735143E-062C-4DD4-BEA3-339B6C3D8AC2Q28206967-426AB9CE-C3C9-4935-A49A-93DCDD4D68B6Q28214721-9BBC68F6-D9C1-4215-BCF0-90EDBF2C86B8Q28241887-DBE03F9F-9E5B-492E-B53C-CC1B550615F9Q28475435-B43CD865-21D2-4710-A469-E90F176E2A8FQ28508757-1C8F295C-1237-498E-8F28-6C6BBBD46C3BQ33618917-65FA1BF4-AB87-4D76-BE4D-212AFC20492EQ33632893-19DAF9CD-F626-41E4-81DE-1DF79B61FBD4Q33843072-6FCD01C9-F379-4625-B925-3ED1D50C4E6AQ33977500-859BD49F-948A-46B4-A57C-E22FFF06C25AQ33982322-1A479794-2D80-4E19-8879-BBD02A984494Q34113773-85203E05-2B53-4280-BAB5-9263197A372CQ34154786-C41FA500-F082-4128-ABCD-CFEF67403B50Q34293019-DBCA3445-838A-40C7-92D3-62EC99EB81C4Q34350760-DE8A31FB-A2AE-4C62-9695-404ABC81BEF1Q34556683-D2F6399D-D97E-4D05-8D1A-959E7B57FDDFQ34595205-7A0BE82C-AD8C-4CD5-8E6A-906E0A244E48Q34641224-5F33FC39-DA39-4A08-B627-8211286B66EFQ35172682-4D499A8F-E74E-4671-8470-3F25B00565D7Q35176496-24F67404-ED06-48D1-8105-2B7CB270175FQ35800446-3C090000-03D8-4ADE-A934-0D3C9A58446AQ35858979-B84ED977-ECA1-4E88-A541-D21CE65EA047Q36107223-DC632A19-140E-4A2F-80F4-EA25DD713AE8Q36164834-AF93345B-9BE8-49DC-B562-304AF269C8CFQ36279243-B2F9C03A-6574-4BC1-B4FC-63FC73C4199AQ36306872-3BE5B740-43CE-45CE-B30D-0D4E9EE6A20FQ36323519-791F6478-56B0-4823-8CA0-9135810A134FQ36441584-E72BAC3E-5BE1-4CD3-8C1A-3E503AC2F2B8Q36508949-26EFC405-38D0-4991-8676-11EC7445741BQ36548417-E9C84887-CE0F-4295-A5D8-2BD47F9516FAQ36576138-F358E2D3-FF00-4D0A-8D7D-140ABD48C882Q36617037-736BFF88-0EA0-4BD0-B763-A94DF8068BE9Q36885561-92BA1A03-C472-426A-9D8B-011EFA61B1E1Q36955078-A780DADB-ADF7-45E5-9ED7-0942DF9905A2Q36982190-C94D086A-6DAD-4110-A196-EB631C0A4A8CQ36996040-25BFF264-D8E8-4375-AD74-9837723ACE57Q37083598-E6C7465F-4CEF-4CEE-99A5-1F993B6FD880Q37091361-25520EFD-709E-4F79-8FEF-254F953BC9F8Q37146068-7600B7E9-FF6D-463F-AAEC-73C594144D7F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stefan N Constantinescu
@en
Stefan N Constantinescu
@es
Stefan N Constantinescu
@sl
Ştefan N. Constantinescu
@hu
type
label
Stefan N Constantinescu
@en
Stefan N Constantinescu
@es
Stefan N Constantinescu
@sl
Ştefan N. Constantinescu
@hu
prefLabel
Stefan N Constantinescu
@en
Stefan N Constantinescu
@es
Stefan N Constantinescu
@sl
Ştefan N. Constantinescu
@hu
P106
P21
P31
P496
0000-0002-8599-2699